Robinhood Asset Management Boosts ResMed Stake

Hedge fund adds over 2,600 shares of medical device maker in Q4

Apr. 7, 2026 at 12:22pm

Got story updates? Submit your updates here. ›

An extreme close-up photograph of the internal gears, circuits, and mechanical parts that make up the core of a ResMed CPAP machine, captured in a cinematic, high-contrast style that emphasizes the robust, precision engineering of the device.ResMed's advanced sleep apnea treatment devices rely on intricate, industrial-grade components to deliver reliable, high-performance respiratory therapy.San Diego Today

Robinhood Asset Management LLC purchased a new stake of 2,622 shares in ResMed Inc. (NYSE:RMD), the medical equipment provider, during the fourth quarter, according to a recent SEC filing. The new position was valued at approximately $632,000.

Why it matters

ResMed is a leading manufacturer of sleep apnea and respiratory care devices, an industry that has seen increased demand as more people seek treatment for sleep disorders. Robinhood's investment in ResMed signals confidence in the company's growth potential and market position.

The details

The new stake in ResMed represents a strategic investment by Robinhood Asset Management, a hedge fund known for its focus on emerging growth opportunities. ResMed's products, which include continuous positive airway pressure (CPAP) machines and related accessories, have seen strong sales as awareness and diagnosis of sleep apnea has increased.

  • Robinhood Asset Management purchased the new ResMed stake in the fourth quarter of 2025.
  • ResMed reported its latest quarterly earnings on January 30, 2026.

The players

Robinhood Asset Management LLC

A hedge fund that focuses on identifying emerging growth opportunities and building strategic investments.

ResMed Inc.

A global medical device company that develops and distributes products for the treatment of sleep apnea and other respiratory conditions.

Got photos? Submit your photos here. ›

What’s next

ResMed is expected to provide an update on its full-year financial guidance when it reports its next quarterly earnings in late April 2026.

The takeaway

Robinhood's investment in ResMed reflects the hedge fund's belief in the long-term growth potential of the sleep apnea treatment market, which continues to expand as more people seek diagnosis and treatment for this common sleep disorder.